Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-VLP tetravalent vaccine
- Development stage
- Preclinical
- Lead developer
- GeoVax Labs
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Intradermal, Percutaneous, Oral
01
Overview
The MVA-VLP tetravalent vaccine is a vaccine candidate developed by GeoVax Labs, Inc. It utilizes a Modified Vaccinia Ankara (MVA) viral vector to deliver Virus-Like Particles (VLPs) designed to elicit an immune response against four hemorrhagic fever viruses: Ebola Zaire, Ebola Sudan, Marburg, and Lassa fever viruses. The vaccine aims to provide broad protection against future outbreaks of these highly pathogenic diseases.
- Other names
- GeoVax Hemorrhagic Fever VaccineMVA-VLP Hemorrhagic Fever Vaccine
02
Targets
CCHFV antigen (Crimean-Congo hemorrhagic fever virus antigen)Zaire ebolavirus glycoproteinLassa virus antigensMarburg virus antigens
Beyond the preview
Go deeper on MVA-VLP tetravalent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-VLP tetravalent vaccine.